Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been formally diagnosed with multiple myeloma using standard international diagnostic guidelines.
- People whose disease is measurable through at least one of the following blood or urine tests (taken within 28 days before enrolling): a specific abnormal protein (M-protein) detected in the blood at a certain level, the same protein detected in urine at a certain level, or abnormal levels of specific proteins called free light chains in the blood — if the M-protein tests are not measurable (confirm with trial site).
- People who have never previously been treated with a type of drug called a BCL-2 inhibitor.
- People whose myeloma has a specific genetic marker called t(11;14) and/or high levels of a protein called BCL2 (confirm with trial site).
- For one part of the trial (Substudy 1 Dose Escalation and Substudy 2): People who have previously been treated with three specific types of myeloma treatment (a proteasome inhibitor, an IMiD, and an anti-CD38 drug), have had between 3 and 5 prior treatment courses, and for whom no other suitable treatment options are considered available by the treating doctor.
- For another part of the trial (Substudy 1 Dose Expansion): People who have previously been treated with two specific types of myeloma treatment (a proteasome inhibitor and an IMiD) and have had between 1 and 3 prior treatment courses.
Who may not be able to join:
- People who have had major surgery within 4 weeks before starting the trial treatment, or who have major surgery planned during the trial period.
- People who have had a serious infection that required systemic (whole-body) treatment, where that treatment finished 7 days or fewer before the first trial dose.
- People who currently have an uncontrolled active infection affecting the whole body.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Dose-Limiting Toxicities (DLT)s of ABBV-453; Number of Participants with Adverse Events (AE)s
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.